{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T10:16:37Z","timestamp":1675764997538},"reference-count":70,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2019.0703","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T05:40:39Z","timestamp":1570772439000},"source":"Crossref","is-referenced-by-count":1,"title":["The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents"],"prefix":"10.3238","author":[{"given":"Tim","family":"Niehues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuba Turul","family":"\u00d6zg\u00fcr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"10.3238\/arztebl.2019.0703_ref1","doi-asserted-by":"crossref","unstructured":"Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM: Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423\u201339","DOI":"10.1002\/ibd.21349"},{"key":"10.3238\/arztebl.2019.0703_ref2","unstructured":"Robert Koch-Institut: RKI, Berlin. Robert Koch-Institut, Gesundheitsberichterstattung des Bundes 2014."},{"key":"10.3238\/arztebl.2019.0703_ref3","unstructured":"Thomschke S, Schulz M, B\u00e4tzing J: Epidemiologie der juvenilen idiopathischen Arthritis (JIA) in der ambulanten Versorgung \u2013 eine Analyse anhand bundesweiter vertrags\u00e4rztlicher Abrechnungsdaten der Jahre 2009 bis 2015. Versorgungsatlas 2018."},{"key":"10.3238\/arztebl.2019.0703_ref4","doi-asserted-by":"crossref","unstructured":"Boyman O, Comte D, Spertini F: Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10: 612\u201327","DOI":"10.1038\/nrrheum.2014.123"},{"key":"10.3238\/arztebl.2019.0703_ref5","doi-asserted-by":"crossref","unstructured":"Davis BP, Ballas ZK: Biologic response modifiers: Indications, implications, and insights. J Allergy Clin Immunol 2017; 139: 1445\u201356","DOI":"10.1016\/j.jaci.2017.02.013"},{"key":"10.3238\/arztebl.2019.0703_ref6","doi-asserted-by":"crossref","unstructured":"Feyen O, Lueking A, Kowald A, et al.: Off-target activity of TNF-alpha inhibitors characterized by protein biochips. Anal Bioanal Chem 2008; 391: 1713\u201320.","DOI":"10.1007\/s00216-008-1938-7"},{"key":"10.3238\/arztebl.2019.0703_ref7","doi-asserted-by":"crossref","unstructured":"Oude Munnink TH, Henstra MJ, Segerink LI, Movig KL, Brummelhuis-Visser P: Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-alpha experience to oncology. Clin Pharmacol Ther 2016; 99: 419\u201331","DOI":"10.1002\/cpt.211"},{"key":"10.3238\/arztebl.2019.0703_ref8","doi-asserted-by":"crossref","unstructured":"Malik P, Edginton A: Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol 2018; 14: 585\u201399","DOI":"10.1080\/17425255.2018.1482278"},{"key":"10.3238\/arztebl.2019.0703_ref9","doi-asserted-by":"crossref","unstructured":"Edlund H, Melin J, Parra-Guillen ZP, Kloft C: Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet 2015; 54: 35\u201380","DOI":"10.1007\/s40262-014-0208-4"},{"key":"10.3238\/arztebl.2019.0703_ref10","unstructured":"NVL-Programm von B\u00c4K, AWMF: Nationale Versorgungs-Leitlinie Asthma. www.awmf.org\/leitlinien\/detail\/ll\/nvl-002.html (last accessed on 12 August 2019)"},{"key":"10.3238\/arztebl.2019.0703_ref11","doi-asserted-by":"crossref","unstructured":"Teach SJ, Gill MA, Togias A, et al.: Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136: 1476\u201385","DOI":"10.1016\/j.jaci.2015.09.008"},{"key":"10.3238\/arztebl.2019.0703_ref12","doi-asserted-by":"crossref","unstructured":"Busse WW, Morgan WJ, Gergen PJ, et al.: Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005\u201315","DOI":"10.1056\/NEJMoa1009705"},{"key":"10.3238\/arztebl.2019.0703_ref13","doi-asserted-by":"crossref","unstructured":"Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF: Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 1210\u20136","DOI":"10.1016\/j.jaci.2009.09.021"},{"key":"10.3238\/arztebl.2019.0703_ref14","doi-asserted-by":"crossref","unstructured":"Milgrom H, Berger W, Nayak A, et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36","DOI":"10.1542\/peds.108.2.e36"},{"key":"10.3238\/arztebl.2019.0703_ref15","unstructured":"arznei-telegramm: Warnung vor Anaphylaxie durch Asthmamittel Omalizumab (Xolair) www.arznei-telegramm.de\/html\/2007_07\/0707071_02.html (last accessed on 12 August 2019)"},{"key":"10.3238\/arztebl.2019.0703_ref16","unstructured":"Deutsche Diabetes Gesellschaft: S2k-Leitlinie Therapie der Psoriasis bei Kindern und Jugendlichen www.awmf.org\/leitlinien\/detail\/ll\/013\u2013094.html (last accessed on 12 August 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref17","doi-asserted-by":"crossref","unstructured":"de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR: Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D 2017; 17: 29\u201351","DOI":"10.1007\/s40268-016-0152-x"},{"key":"10.3238\/arztebl.2019.0703_ref18","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al.: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12: CD011535","DOI":"10.1002\/14651858.CD011535.pub2"},{"key":"10.3238\/arztebl.2019.0703_ref19","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Whitworth P, Baildam EM: Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197\u2013200","DOI":"10.1136\/adc.88.3.197"},{"key":"10.3238\/arztebl.2019.0703_ref20","doi-asserted-by":"crossref","unstructured":"Papp K, Thaci D, Marcoux D, et al.: Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017; 390: 40\u20139","DOI":"10.1016\/S0140-6736(17)31189-3"},{"key":"10.3238\/arztebl.2019.0703_ref21","doi-asserted-by":"crossref","unstructured":"Paller AS, Siegfried EC, Langley RG, et al.: Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241\u201351","DOI":"10.1056\/NEJMoa066886"},{"key":"10.3238\/arztebl.2019.0703_ref22","doi-asserted-by":"crossref","unstructured":"Landells I, Marano C, Hsu MC, et al.: Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594\u2013603","DOI":"10.1016\/j.jaad.2015.07.002"},{"key":"10.3238\/arztebl.2019.0703_ref23","doi-asserted-by":"crossref","unstructured":"Dueckers G, Guellac N, Arbogast M, et al.: Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 2012; 142: 176\u201393","DOI":"10.1016\/j.clim.2011.10.003"},{"key":"10.3238\/arztebl.2019.0703_ref24","doi-asserted-by":"crossref","unstructured":"Ruperto N, Lovell DJ, Cuttica R, et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096\u2013106","DOI":"10.1002\/art.22838"},{"key":"10.3238\/arztebl.2019.0703_ref25","doi-asserted-by":"crossref","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al.: Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012; 64: 2012\u201321","DOI":"10.1002\/art.34343"},{"key":"10.3238\/arztebl.2019.0703_ref26","doi-asserted-by":"crossref","unstructured":"Tynj\u00e4l\u00e4 P, Vahasalo P, Tarkiainen M, et al.: Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis 2011; 70: 1605\u201312","DOI":"10.1136\/ard.2010.143347"},{"key":"10.3238\/arztebl.2019.0703_ref27","doi-asserted-by":"crossref","unstructured":"Hissink M\u00fcller PC, Brinkman DM, Schonenberg D, et al.: A comparison of three treatment strategies in recent onset non-systemic juvenile idiopathic arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J 2017; 15: 11","DOI":"10.1186\/s12969-017-0138-4"},{"key":"10.3238\/arztebl.2019.0703_ref28","doi-asserted-by":"crossref","unstructured":"Burgos-Vargas R, Tse SM, Horneff G, et al.: A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken) 2015; 67: 1503\u201312","DOI":"10.1002\/acr.22657"},{"key":"10.3238\/arztebl.2019.0703_ref29","doi-asserted-by":"crossref","unstructured":"Horneff G, Fitter S, Foeldvari I, et al.: Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012; 14: R230","DOI":"10.1186\/ar4072"},{"key":"10.3238\/arztebl.2019.0703_ref30","doi-asserted-by":"crossref","unstructured":"Quartier P, Allantaz F, Cimaz R, et al.: A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747\u201354","DOI":"10.1136\/ard.2010.134254"},{"key":"10.3238\/arztebl.2019.0703_ref31","doi-asserted-by":"crossref","unstructured":"Ruperto N, Quartier P, Wulffraat N, et al.: A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557\u201367","DOI":"10.1002\/art.33342"},{"key":"10.3238\/arztebl.2019.0703_ref32","doi-asserted-by":"crossref","unstructured":"de Benedetti F, Brunner HI, Ruperto N, et al.: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385\u201395","DOI":"10.1056\/NEJMoa1112802"},{"key":"10.3238\/arztebl.2019.0703_ref33","doi-asserted-by":"crossref","unstructured":"Yokota S, Imagawa T, Mori M, et al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998\u20131006","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"10.3238\/arztebl.2019.0703_ref34","doi-asserted-by":"crossref","unstructured":"Horneff G, Foeldvari I, Minden K, et al.: Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Arthritis Rheumatol 2015; 67: 2240\u20139","DOI":"10.1002\/art.39145"},{"key":"10.3238\/arztebl.2019.0703_ref35","doi-asserted-by":"crossref","unstructured":"Ruperto N, Lovell DJ, Quartier P, et al.: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383\u201391","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"10.3238\/arztebl.2019.0703_ref36","doi-asserted-by":"crossref","unstructured":"Lovell DJ, Ruperto N, Goodman S, et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810\u201320","DOI":"10.1056\/NEJMoa0706290"},{"key":"10.3238\/arztebl.2019.0703_ref37","doi-asserted-by":"crossref","unstructured":"Lovell DJ, Giannini EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763\u20139","DOI":"10.1056\/NEJM200003163421103"},{"key":"10.3238\/arztebl.2019.0703_ref38","doi-asserted-by":"crossref","unstructured":"Brunner HI, Ruperto N, Zuber Z, et al.: Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110\u20137","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"10.3238\/arztebl.2019.0703_ref39","doi-asserted-by":"crossref","unstructured":"Brunner HI, Rider LG, Kingsbury DJ, et al.: Pediatric Rheumatology Collaborative Study Group \u2013 over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatr Rheumatol Online J 2018; 16: 45","DOI":"10.1186\/s12969-018-0261-x"},{"key":"10.3238\/arztebl.2019.0703_ref40","unstructured":"Deutsche Ophthalmologische Gesellschaft: Diagnostik und antientz\u00fcndliche Therapie der Uveitis bei juveniler idiopathischer Arthritis. (last accessed on 13 August 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref41","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Dick AD, Jones AP, et al.: Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637\u201346","DOI":"10.1056\/NEJMoa1614160"},{"key":"10.3238\/arztebl.2019.0703_ref42","doi-asserted-by":"crossref","unstructured":"Smith JA, Thompson DJ, Whitcup SM, et al.: A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18\u201323","DOI":"10.1002\/art.20904"},{"key":"10.3238\/arztebl.2019.0703_ref43","doi-asserted-by":"crossref","unstructured":"Swart J, Giancane G, Horneff G, et al.: Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018; 20: 285","DOI":"10.1186\/s13075-018-1780-z"},{"key":"10.3238\/arztebl.2019.0703_ref44","doi-asserted-by":"crossref","unstructured":"Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A: Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 2517\u201324","DOI":"10.1002\/art.27511"},{"key":"10.3238\/arztebl.2019.0703_ref45","doi-asserted-by":"crossref","unstructured":"Simard JF, Neovius M, Hagelberg S, Askling J: Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 3776\u201382","DOI":"10.1002\/art.27741"},{"key":"10.3238\/arztebl.2019.0703_ref46","doi-asserted-by":"crossref","unstructured":"Kemanetzoglou E, Andreadou E: CNS demyelination with TNF-alpha blockers. Curr Neurol Neurosci Rep 2017; 17: 36","DOI":"10.1007\/s11910-017-0742-1"},{"key":"10.3238\/arztebl.2019.0703_ref47","doi-asserted-by":"crossref","unstructured":"Kakkassery V, Mergler S, Pleyer U: Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010; 35: 751\u20136","DOI":"10.3109\/02713683.2010.486520"},{"key":"10.3238\/arztebl.2019.0703_ref48","doi-asserted-by":"crossref","unstructured":"Barthel D, Ganser G, Kuester RM, et al.: Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol 2015; 42: 2160\u20135","DOI":"10.3899\/jrheum.140472"},{"key":"10.3238\/arztebl.2019.0703_ref49","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten: S3-Leitlinie 021\/004: Diagnostik und Therapie des Morbus Crohn www.awmf.org\/leitlinien\/detail\/ll\/021\u2013004.html (last accessed on 2 September 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref50","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten: S3 Leitlinie 021\u2013009 Diagnostik und Therapie der Colitis ulcerosa. www.kompetenznetz-darmerkrankungen.de\/files\/cto_layout\/img\/Diagnostik-und-Therapie-der-Colitis-ulcerosa.pdf (last accessed on on 2 September 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref51","doi-asserted-by":"crossref","unstructured":"Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN: Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2018s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther 2017; 45: 1291\u2013302","DOI":"10.1111\/apt.14030"},{"key":"10.3238\/arztebl.2019.0703_ref52","doi-asserted-by":"crossref","unstructured":"D\u00e4britz J, Gerner P, Enninger A, Cla\u00dfen M, Radke M: Inflammatory bowel disease in childhood and adolescence\u2014diagnosis and treatment. Dtsch Arztebl Int 2017; 114: 331\u20138","DOI":"10.3238\/arztebl.2017.0331"},{"key":"10.3238\/arztebl.2019.0703_ref53","doi-asserted-by":"crossref","unstructured":"Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265\u20137","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"10.3238\/arztebl.2019.0703_ref54","unstructured":"Ethical considerations for clinical trials on medicinal products conducted with minors. Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536\/2014 on clinical trials on medicinal products for human use. www.ec.europa. eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/2017_09_18_ethical_ consid_ct_with_minors.pdf (last accessed on 12.-August 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref55","unstructured":"Windeler J, Lauterberg J, Wieseler B, Sauerland S: Patientenregister f\u00fcr die Nutzenbewertung: Kein Ersatz f\u00fcr randomisierte Studien. Dtsch Arztebl 2017; 114(16): A-783\u20136."},{"key":"10.3238\/arztebl.2019.0703_ref56","unstructured":"Gesellschaft f\u00fcr Kinder- und Jugendrheumatologie: Forschungsprojekte in der Kinderrheumatologie. www.gkjr.de\/forschungsprojekte\/forschungsprojekte-in-der-kinderrheumatologie\/ (last accessed on 12 August 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref57","unstructured":"UN-Kinderrechtskonvention: \u00dcbereinkommen \u00fcber die Rechte des Kindes (Convention on the Rights of the Child, CRC). www.kinderrechtskonvention.info\/ (last accessed on 12 August 2019)."},{"key":"10.3238\/arztebl.2019.0703_ref58","doi-asserted-by":"crossref","unstructured":"Pocock SJ: The pros and cons of noninferiority trials. Fundam Clin Pharmacol 2003; 17: 483\u201390","DOI":"10.1046\/j.1472-8206.2003.00162.x"},{"key":"10.3238\/arztebl.2019.0703_ref59","doi-asserted-by":"crossref","unstructured":"Feldman B, Wang E, Willan A, Szalai JP: The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001; 54: 550\u20137","DOI":"10.1016\/S0895-4356(00)00357-7"},{"key":"10.3238\/arztebl.2019.0703_ref60","doi-asserted-by":"crossref","unstructured":"Demirkaya E, Lanni S, Bovis F, et al.: A meta-analysis to estimate\u00a0the placebo effect in randomized controlled trials in juvenile idiopathic arthritis. Arthritis Rheumatol 2016; 68: 1540\u201350","DOI":"10.1002\/art.39583"},{"key":"10.3238\/arztebl.2019.0703_ref61","doi-asserted-by":"crossref","unstructured":"Abrahamyan L, Feldman BM, Tomlinson G, et al.: Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet 2016; 172: 313\u201331","DOI":"10.1002\/ajmg.c.31533"},{"key":"10.3238\/arztebl.2019.0703_ref62","doi-asserted-by":"crossref","unstructured":"Lehman TJ: Are withdrawal trials in paediatric rheumatic disease helpful? Lancet 2008; 372: 348\u201350","DOI":"10.1016\/S0140-6736(08)60999-X"},{"key":"10.3238\/arztebl.2019.0703_ref63","doi-asserted-by":"crossref","unstructured":"Boyman O, Comte D, Spertini F: Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10: 612\u201327","DOI":"10.1038\/nrrheum.2014.123"},{"key":"10.3238\/arztebl.2019.0703_ref64","doi-asserted-by":"crossref","unstructured":"Davis BP, Ballas ZK: Biologic response modifiers: Indications, implications, and insights. J Allergy Clin Immunol 2017; 139: 1445\u201356","DOI":"10.1016\/j.jaci.2017.02.013"},{"key":"10.3238\/arztebl.2019.0703_ref65","doi-asserted-by":"crossref","unstructured":"Picard M, Galvao VR: Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract 2017; 5: 600\u20139","DOI":"10.1016\/j.jaip.2016.12.001"},{"key":"10.3238\/arztebl.2019.0703_ref66","doi-asserted-by":"crossref","unstructured":"Corren J, Kavati A, Ortiz B, et al.: Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc 2017; 38: 250\u201363","DOI":"10.2500\/aap.2017.38.4067"},{"key":"10.3238\/arztebl.2019.0703_ref67","doi-asserted-by":"crossref","unstructured":"Ehmann LM, Tillack-Schreiber C, Brand S, Wollenberg A: Malignant melanoma during ustekinumab therapy of Crohn\u2018s disease. Inflamm Bowel Dis 2012; 18: E199\u2013200","DOI":"10.1002\/ibd.21877"},{"key":"10.3238\/arztebl.2019.0703_ref68","doi-asserted-by":"crossref","unstructured":"Young L, Czarnecki D: The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 2012; 53: 57\u201360","DOI":"10.1111\/j.1440-0960.2011.00853.x"},{"key":"10.3238\/arztebl.2019.0703_ref69","doi-asserted-by":"crossref","unstructured":"Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P: Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 2011; 147: 1197\u2013202","DOI":"10.1001\/archdermatol.2011.161"},{"key":"10.3238\/arztebl.2019.0703_ref70","doi-asserted-by":"crossref","unstructured":"Niehues T: Therapeutic monoclonal antibodies as immunomodulators and anti-cancer agents: development, evidence of efficacy, mechanisms of actions, adverse effects in antibody therapy. In: Imbach P, eds.: Antibody therapy, substitution \u2013 immunomodulation \u2013 monoclonal immunotherapy Springer Verlag 2018; 291\u2013341","DOI":"10.1007\/978-3-319-68038-5_20"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:28:50Z","timestamp":1638786530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2019.0703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":70,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2019.0703","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]}}}